Human VEGFA / VEGFR2 Inhibitor Screening Kit (TR-FRET)

• Comprehensive validation - Validated with various antibody drugs.
• Simple and fast operation - No complicated washing steps, significantly reducing time.
• High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
• Accurate and reliable results - High sensitivity with minimal matrix effects.
• High throughput capability - Support multiple product specifications, ideal for high-throughput screening.
• Fast completion - Results in just 1 hour.

The Human VEGFA / VEGFR2 Inhibitor Screening Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to screen for inhibitors of human VEGFA binding to VEGFR2 within one hour. It can also be used as a universal detection tool to identify the ability of human VEGFA to bind to human VEGFR2.

1. Unopened kit should be stored at 2℃-8℃ upon receiving.

2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

This Human VEGFA / VEGFR2 Inhibitor Screening Kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). This assay uses the mixture of biotinylated human VEGF165 and Europium-chelate labeled streptavidin as the Donor and FA Labeled Human VEGFR2 Protein as the Acceptor.

— When the sample does not contain the inhibitors that block the binding of human VEGF165 to human VEGFR2, the Donor and Acceptor are in close proximity because of the binding of human VEGF165 and human VEGFR2. Upon Donor excitation with light of a specific wavelength (337nm), in addition to Donor emission (620nm), non-radiative transfer of energy occurs between Donor and Acceptor, resulting in Acceptor emission (665nm).

— When the sample contains the inhibitors that block the binding of human VEGF165 to human VEGFR2, the components inhibit the binding between the Donor and Acceptor and thereby prevent FRET from occurring.